← All organizations
Highest phase reached
Phase 4
First clinical trial
Aug 1, 2002First marketed drug
Mar 16, 2005First NDA
Mar 16, 2005Last known activity
Jun 1, 2015
Acquired by Bristol-Myers Squibb on Jan 1, 2012
Timeline
1980s
- Jan 1, 1987
Amylin— Founded
2010s
- Jan 1, 2012
Bristol-Myers Squibb— Acquired By
- Feb 24, 2014
metreleptin— NDA Organization
Drugs by trial phase (20 distinct, 61 trials)
Phase 4 (9 own, 0 via acquisition)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (7 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Other trials (2 own, 0 via acquisition)
Indications
Studied for
- Acute Coronary Syndrome
- Body Weight
- Cardiovascular Diseases
- Diabetes Complications
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Fatty Liver
- Glucose Intolerance
- Heart Failure
- Hyperglycemia
- Hypoglycemia
- Infarction
- Insulin Resistance
- Lipodystrophy
- Liver Diseases
- Myocardial Infarction
- Non-alcoholic Fatty Liver Disease
- Obesity
- Overweight
- Polycystic Ovary Syndrome
- Prediabetic State
- Psychotic Disorders
- Schizophrenia
- Syndrome
- Weight Gain
- Weight Loss
Marketed drugs (3)
Recent trials (50)
- NCT02443922CollaboratorN/AJun 1, 2015
- NCT01652716Study directorPhase 3Jan 1, 2013
- NCT01501084CollaboratorN/ADec 1, 2011
- NCT01381926CollaboratorPhase 4Feb 1, 2011
- NCT01297062Study directorPhase 1Feb 1, 2011
- NCT01235741Study directorPhase 2Jan 1, 2011
- NCT01364584CollaboratorN/AOct 1, 2010
- NCT01268644CollaboratorPhase 1Sep 1, 2010
- NCT01147627CollaboratorN/AAug 1, 2010
- NCT01181986CollaboratorPhase 4Aug 1, 2010
- NCT01588418CollaboratorPhase 4Jul 1, 2010
- NCT01104701Study directorPhase 2May 1, 2010
- NCT01137695CollaboratorPhase 3May 1, 2010
- NCT01061775CollaboratorPhase 1/Phase 2Jan 1, 2010
- NCT01165944CollaboratorPhase 1/Phase 2Aug 1, 2009
Details
- Founded
- San Diego, CA, US Jan 1, 1987
- First NDA
- Mar 16, 2005
- Last known activity
- Jun 1, 2015
Designations held
- Orphan drug
- Fast track
Notes
Acquired by Bristol Myers Squibb 1 Jul 2012